CD274 and non-small cell lung carcinoma: This proof-of concept study demonstrated the feasibility of PD-L1 testing in plasma samples of patients with advanced NSCLC, showing that the cPD-L1 expression levels may be significantly modified by the standard first-line chemotherapy.